DVx
3079.T
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 |
|---|---|---|
| Revenue | ¥56.0bn | — |
| Operating income | ¥294m | — |
| Ordinary income | ¥301m | — |
| Net income (owners) | ¥225m | — |
| Total assets | ¥25.0bn | — |
| Net assets / equity | ¥8.8bn | ¥9.1bn |
| Operating cash flow | −¥1.2bn | — |
| EPS (basic) | ¥21.49 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 48 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 118 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales |
|---|---|
| Arrhythmia Business | ¥45.7bn |
| Ischemia Business | ¥4.0bn |
| Other segments | ¥6.3bn |
| Total | ¥49.7bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.